Marcia Belvin - Aug 20, 2024 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
SVP, Chief Scientific Officer
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Marcia Belvin
Stock symbol
CTMX
Transactions as of
Aug 20, 2024
Transactions value $
-$5,139
Form type
4
Date filed
8/22/2024, 06:01 PM
Previous filing
Mar 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $0 +11.3K +6.67% $0.00 180K Aug 20, 2024 Direct F1, F2
transaction CTMX Common Stock Sale -$5.14K -4.18K -2.32% $1.23 176K Aug 20, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Performance Stock Units (PSUs) Options Exercise $0 -11.3K -100% $0.00 0 Aug 20, 2024 Common Stock 11.3K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents vesting of a Performance Stock Unit ("PSU") award initially granted on August 10, 2022.
F2 Includes 109,166 restricted stock units.
F3 The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of PSUs reported herein.
F4 Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. 50% of the PSUs vested on December 17, 2023 upon achievement of a certain performance-based milestone. In connection with the vesting reported herein, the remaining 50% of the PSUs vested upon achievement of a certain performance-based milestone.